Novoheart Licenses Harvard Technology to Develop Next-Generation Human Heart-in-a-Jar
16 déc. 2019 03h05 HE
|
Novoheart Holdings Inc.
Novoheart engineered the world’s first “human heart-in-a-jar” as part of its proprietary MyHeart™ platformNovoheart receives exclusive license from Harvard University to integrate pioneering...
Novoheart Announces Change of Fiscal Year-End and Grants Stock Options
29 nov. 2019 21h00 HE
|
Novoheart Holdings Inc.
VANCOUVER, British Columbia, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announced that it is changing its fiscal year-end to...
Novoheart Provides Corporate Update
29 nov. 2019 20h00 HE
|
Novoheart Holdings Inc.
VANCOUVER, British Columbia, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announced today that Joseph Leung resigned as Chief...
Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZeneca
26 nov. 2019 00h02 HE
|
Novoheart Holdings Inc.
Heart failure is a global pandemic with an estimated 64.3 million cases worldwide in 2017, costing over US$100B per yearDrug developers currently lack effective humanized models for preclinical...
Novoheart Holdings Inc. Reports First Quarter 2020 Financial Results
19 nov. 2019 19h00 HE
|
Novoheart Holdings Inc.
VANCOUVER, British Columbia, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three months ended September 30, 2019....
Novoheart Grants Stock Options
08 oct. 2019 23h00 HE
|
Novoheart Holdings Inc.
VANCOUVER, British Columbia, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announces that it has granted incentive stock options to...
Two new Pfizer-coauthored studies validate Novoheart’s pioneering human bioengineered heart tissues and chambers for improving drug development
09 sept. 2019 00h05 HE
|
Novoheart Holdings Inc.
Novoheart seeks to revolutionize human heart tissue engineering for disease modeling and drug discovery Peer-reviewed publications feature results from the completion of two research contracts between...
Novoheart Holdings Inc. Reports Fourth Quarter and Fiscal 2019 Financial Results
05 sept. 2019 07h00 HE
|
Novoheart Holdings Inc.
VANCOUVER, British Columbia, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three and twelve months ended June 30, 2019....
Novoheart Holdings Inc. Completes Acquisition of Xellera Therapeutics
29 juin 2019 00h32 HE
|
Novoheart Holdings Inc.
VANCOUVER, British Columbia, June 29, 2019 (GLOBE NEWSWIRE) -- Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) is pleased to announce that it has completed its...
Novoheart Announces Appointment of New Chief Financial Officer
17 juin 2019 03h00 HE
|
Novoheart Holdings Inc.
VANCOUVER, British Columbia, June 17, 2019 (GLOBE NEWSWIRE) -- Novoheart Holdings Inc. (“Novoheart” or the “Company”) announced the appointment of Joseph Leung (“Joseph”) as its new Chief Financial...